Iovance Biotherapeutics (IOVA) Stock Looks Cheap On Sales While Returns Stay Weak
Iovance Biotherapeutics stock has delivered a strong rebound over the past year, yet longer term holders are still facing steep losses, so the current valuation attracts close attention. The share price now sits against a backdrop where the broader checks lean cheap. This raises the question of whether the market is still underpricing the company or simply adjusting after a difficult few years.
- Over 5 years, Iovance Biotherapeutics is down 82.7%, which means many long term investors are still deep in the red despite the recent recovery.
- The company’s potential to convert its pipeline into sustainable revenue can support the current price, while the risk that cash needs stay high before those revenues materialize may weigh on what investors are willing to pay.
- The broader valuation checks lean cheap, with Iovance Biotherapeutics screening as undervalued in 5 of 6 tests according to its value score of 5.
The issue now is whether that apparently favorable valuation is enough to compensate investors for the company specific risks that have driven such weak long term returns.
Is Iovance Biotherapeutics Still Cheap on Sales?
The P/S ratio suits Iovance Biotherapeutics because investors are mainly focused on its revenue potential rather than current profits. On this measure, the stock trades at around 6.4x sales, which is below the broader biotech industry average of about 10.5x and also below the peer group average of roughly 27.6x.
A tailored fair P/S ratio for Iovance Biotherapeutics is estimated at about 7.1x, which takes into account its size, risk profile and revenue outlook. The current valuation sits under that level, so the stock screens as undervalued on this framework even before considering that it also trades at a discount to the wider biotech group.
On the P/S multiple, Iovance Biotherapeutics appears undervalued compared with both its custom fair ratio and typical biotech peers.
See what the numbers say about this price — find out in our valuation breakdown.
The Iovance Biotherapeutics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Iovance Biotherapeutics valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price, and they sit on the company’s Community page. Rather than relying on a single multiple or model output, each one lays out its key assumptions so you can compare them with Iovance Biotherapeutics' actual results over time.
Iovance Biotherapeutics has drawn out sharply different community views, with some holders seeing a recovery story while others stay focused on funding and execution risks.
Bull case: 77% undervalued
"The biggest difference is that Iovance is no longer waiting for its first product to be approved, Amtagvi is already approved in the United States and is the first TIL (tumor-infiltrating lymphocyte) therapy available for patients with advanced melanoma…"
Read the full Bull Case to see why Iovance Biotherapeutics could be undervalued
Bear case: roughly fairly valued
"The commercialization pathway for TIL-based therapies remains complex and slow, as evidenced by the need to pivot distribution channels and the stop-start ATC activation process, signaling that projected revenue ramps may be overstated and sustainable profitability will be delayed well beyond the current guidance…"
Read the full Bear Case to see why Iovance Biotherapeutics could be overvalued
Do you think there's more to the story for Iovance Biotherapeutics? Head over to our Community to see what others are saying!
The Bottom Line
Iovance Biotherapeutics screens as undervalued on its sales multiple, with the broader checks also pointing to a relatively attractive valuation. That potential discount only matters if the company can turn its pipeline and first approved therapy into meaningful and durable revenue, while keeping funding and execution risks contained. For now, the crux of the debate is whether the current valuation reflects an opportunity or fairly prices the chance that commercialization proves slower and more costly than optimistic scenarios assume.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com